[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100272328":3},{"organization":4,"armGroups":7,"interventions":42,"overallOfficials":51,"centralContacts":56,"locations":61,"responsibleParty":91,"collaborators":95,"id":100,"slug":46,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":46,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":46,"enrollmentInfo":108,"targetDuration":46,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":64,"whyStopped":46,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Technische Universität Dresden","OTHER",[8,14,20,24,28,31,34,38],{"label":9,"type":10,"description":11,"interventionNames":12},"supratentorial, grade III\u002FIV, photon","ACTIVE_COMPARATOR","Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.",[13],"Radiation: Radiation with photons",{"label":15,"type":16,"description":17,"interventionNames":18},"supratentorial, grade III\u002FIV, proton","EXPERIMENTAL","Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.",[19],"Radiation: Radiation with protons",{"label":21,"type":10,"description":22,"interventionNames":23},"supratentorial, grade I\u002FII, photon","Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"supratentorial, grade I\u002FII, proton","Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients, bening tumors.",[19],{"label":29,"type":10,"description":11,"interventionNames":30},"infratentorial, photon",[13],{"label":32,"type":16,"description":17,"interventionNames":33},"infratentorial, proton",[19],{"label":35,"type":10,"description":36,"interventionNames":37},"pre-radiation, photon","\\> 40Gy in the region of recurrence. Radiation with photons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)\u002Ffraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).",[13],{"label":39,"type":16,"description":40,"interventionNames":41},"pre-radiation, proton","\\> 40Gy in the region of recurrence. Radiation with protons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)\u002Ffraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).",[19],[43,48],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":46},"RADIATION","Radiation with protons",null,[32,39,25,15],{"type":44,"name":49,"description":46,"armGroupLabels":50,"otherNames":46},"Radiation with photons",[29,35,21,9],[52],{"name":53,"affiliation":54,"role":55},"Mechthild Krause, Prof.","University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)","STUDY_CHAIR",[57],{"name":53,"role":58,"phone":59,"phoneExt":46,"email":60},"CONTACT","+49 351 458 5441","mechthild.krause@uniklinikum-dresden.de",[62,77],{"facility":63,"status":64,"city":65,"state":46,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"University Hospital Carl Gustav Carus, Department of Radiotherapy and Radiation Oncology","RECRUITING","Dresden","01307","Germany","DE",{"type":70,"coordinates":71},"Point",[72,73],13.73832,51.05089,{"lat":73,"lon":72},[76],{"name":53,"role":58,"phone":59,"phoneExt":46,"email":60},{"facility":78,"status":64,"city":79,"state":46,"zip":80,"country":67,"countryCode":68,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"University Hospital Gießen and Marburg, Department of Radiotherapy and Radiation Oncology","Marburg","35043",{"type":70,"coordinates":82},[83,84],8.77069,50.80904,{"lat":84,"lon":83},[87],{"name":88,"role":58,"phone":89,"phoneExt":46,"email":90},"Sebastian Adeberg, Prof. Dr.","+496421-5868074","Studien.Radioonkologie.MR@uk-gm.de",{"type":92,"investigatorFullName":93,"investigatorTitle":94,"investigatorAffiliation":5,"oldNameTitle":46,"oldOrganization":46},"PRINCIPAL_INVESTIGATOR","Mechthild Krause","Principal Investigator",[96,98],{"name":97,"class":6},"German Cancer Research Center",{"name":99,"class":6},"National Center for Radiation Research in Oncology Dresden\u002FHeidelberg","100272328",false,"NCT02824731","Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn)","Comparison of Proton and Photon Radiotherapy of Brain Tumors: Efficiency and Side Effects in Clinical Standard Doses","Inclusion Criteria:\n\n* primary brain tumor: gliomas (low or high grade), intracerebral meningiomas, pituitary adenomas, craniopharyngioma and other rare brain tumors or\n* brain tumor recurrence without pre-irradiation or\n* brain tumor recurrence with pre-irradiation \\> 40 Gy in the overlap region with the recurrence region\n* indication for radiotherapy or radiochemotherapy\n* Both proton and photon therapy are possible from a medical point of view (that is no standard indication for protons or standard indication for example one-time stereotaxy\n* age \\>= 18 years\n* general condition ECOG ≤ 2, outpatient basis possible\n* indication for high dose (except group 4) radiotherapy or radiochemotherapy\n* capacity to consent and present written informed consent\n\nExclusion Criteria:\n\n* lack of capacity to consent or lack of written consent\n* cerebral lymphomas\n* brain metastases\n* very small tumors (for example acoustic neuromas, very small recurrences) for this is a proton therapy from a medical point of view no alternative to a stereotactic radiotherapy\n* inability to MRI planning (eg. contraindications to performing MRI)\n* lack of compliance of the patient\n* lack of or limited possibility of a reproducible storage (eg by severe restriction of mobility of the patient)\n* missing or limited possibility of regular follow-up visits in accordance with the study protocol","ALL","18 Years",{"count":109,"type":110},555,"ESTIMATED","INTERVENTIONAL",[113],"NA","This protocol compares the toxicity of radiotherapy or radiochemotherapy applied with different radiation modalities - protons or photons. Patients with different kinds of brain tumours and foreseen high-dose radiotherapy can be included. The hypothesis of the trial is that the rate of chronic toxicity 1 year after the end of radiotherapy is 15% lower after proton compared to photon treatment.",[116],"Brain Tumors",[118,119,120],"brain tumors","proton radiotherapy","photon radiotherapy","2024-12-11",{"date":123,"type":124},"2024-12-16","ACTUAL",{"date":126,"type":124},"2016-07",{"date":128,"type":110},"2029-10",{"name":5,"class":6},2]